Radboud universitair medisch centrum Stichting
Radboud universitair medisch centrum Stichting is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options
Sponsor Mundipharma Research Limited
- Start (EU)
- Latest update
- Estimated end
A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma
Sponsor Universitair Medisch Centrum Groningen
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Sponsor Elion Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response
Sponsor Universiteit Maastricht
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Radboud universitair medisch centrum Stichting?
The 2026-10-09 snapshot links Radboud universitair medisch centrum Stichting to 4 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Radboud universitair medisch centrum Stichting?
The most frequently recorded therapeutic areas are Infectious Disease, Respiratory, Haematological Malignancies. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Radboud universitair medisch centrum Stichting conducted?
The linked trials record locations in 8 countries, including Netherlands, Belgium, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where Radboud universitair medisch centrum Stichting delivered services.
What can this page tell me about Radboud universitair medisch centrum Stichting's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Radboud universitair medisch centrum Stichting. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Radboud universitair medisch centrum Stichting